Recently the British Pharmacopoeia celebrated 150 years of publication.
The British Pharmacopoeia (BP) is an annual published collection of quality standards for UK medicinal substances. It is used by individuals and organizations involved in pharmaceutical research, development, manufacture and testing. The current structure of the pharmacopoeia is:
Medicinal Substances
Formulated Preparations
Blood related Preparations
Immunological Products
Radiopharmaceutical Preparations
Surgical Materials
Homeopathic Preparations
Appendices
Infrared Reference Spectra
Index
British Pharmacopoeia (Veterinary)
British Pharmacopoeia
British Pharmacopoeia (Veterinary)
British Approved Names
To celebrate this landmark anniversary the Medicines Healthcare Products Regulatory Agency (MHRA) is hosting a special event “The Quality of Medicines – Future Evolution” on 9 April 2014 which brings together international regulators, pharmacopoeial authorities and the pharmaceutical industry, providing a unique opportunity to collaborate.
Topics on the agenda include:
Posted by Tim Sandle
The British Pharmacopoeia (BP) is an annual published collection of quality standards for UK medicinal substances. It is used by individuals and organizations involved in pharmaceutical research, development, manufacture and testing. The current structure of the pharmacopoeia is:
Volumes I and II
Medicinal Substances
Volume III
Formulated Preparations
Blood related Preparations
Immunological Products
Radiopharmaceutical Preparations
Surgical Materials
Homeopathic Preparations
Volume IV
Appendices
Infrared Reference Spectra
Index
Volume V
British Pharmacopoeia (Veterinary)
Volume VI
British Pharmacopoeia
British Pharmacopoeia (Veterinary)
British Approved Names
To celebrate this landmark anniversary the Medicines Healthcare Products Regulatory Agency (MHRA) is hosting a special event “The Quality of Medicines – Future Evolution” on 9 April 2014 which brings together international regulators, pharmacopoeial authorities and the pharmaceutical industry, providing a unique opportunity to collaborate.
Topics on the agenda include:
- data integrity considerations in Good Manufacturing Practice Quality Control (GMP QC) laboratories.
- harmonisation and the latest technological developments in biological, biosimilar medicines and innovations such as quality by design.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources